The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease
Open accessAbstract
BACKGROUND: Crohn's disease (CD) is a chronic inflammatory disorder that can involve any part of the gastrointestinal tract. 5-Aminosalicylates (5-ASAs) are locally acting, anti-inflammatory compounds that reduce inflammation of the colonic mucosa with release profiles that vary among various commercially available formulations. This updated Cochrane review summarizes current evidence on the use of 5-ASA formulations for maintenance of surgically-induced remission in CD. OBJECTIVES: To assess the efficacy and safety of 5-ASA agents for the maintenance of surgically-induced remission in CD. SEARCH METHODS: We searched MEDLINE, Embase, CENTRAL, the Cochrane IBD Group Specialized Register from inception to 16 July 2018. We also searched references, conference abstracts, and trials registers. SELECTION CRITERIA: Randomised controlled trials (RCTs) that included participants with CD in remission following surgery and compared 5-ASAs to no treatment, placebo or any other active intervention with duration of at least three months were considered for inclusion. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. The primary outcome was clinical relapse. Secondary outcomes included endoscopic recurrence, radiologic and surgical relapse, adverse events, serious adverse events and withdrawal due to adverse events. MAIN RESULTS: Fourteen RCTs (1867 participants) were included in the review. Participants (15 to 70 years) were recruited from gastroenterology hospitals and medical clinics in Europe and North America and followed up between 3 and 72 months. The risk of bias was assessed as 'low' in one study, 'unclear' in seven and as 'high' in six.At 12 months, 36% (20/55) of participants in the 5-ASA group experienced clinical relapse compared to 51% (28/55) in the no treatment control group (RR 0.71, 95% CI 0.46 to 1.10; low certainty evidence). Moderate certainty evidence suggests that 5-ASAs are more effective for preventing clinical relapse than placebo. During a follow-up period of 12 to 72 months, 36% (131/361) of 5-ASA participants relapsed compared to 43% (160/369) of placebo participants (RR 0.83, 95% CI 0.72 to 0.96; I² = 0%; moderate certainty evidence). At 12 months, 17% (17/101) of the 4 g/day mesalamine group relapsed compared to 26% (27/105) of the 2.4 g/day group (RR 0.65, 95% CI 0.38 to 1.13; moderate certainty evidence). There was no evidence of a difference in clinical relapse rates when 5-ASA compounds were compared to purine antimetabolites. At 24 months, 61% (103/170) of mesalamine participants relapsed compared to 67% (119/177) of azathioprine participants (RR 0.90, 95% CI 0.76 to 1.07; I² = 28%; low certainty evidence). During 24 months, 50% (9/18) of 5-ASA participants had clinical relapse compared to 13% (2/16) of adalimumab participants (RR 4.0, 95% CI 1.01 to 15.84; low certainty evidence). The effects of sulphasalazine compared to placebo on clinical relapse rate is uncertain. After 18 to 36 months, 66% (95/143) of participants treated with sulphasalazine relapsed compared to 71% (110/155) in the placebo group (RR 0.88, 95% CI 0.56 to 1.38; I² = 38%; low certainty evidence).The effect of 5-ASA drugs on safety was uncertain. During 24 months follow-up, 4% (2/55) of 5-ASA participants experienced adverse events compared to none (0/55) in the no treatment control group (RR 5.00, 95% CI 0.25 to 101.81; very low certainty evidence). An equal proportion of 5-ASA participants (10%; 23/241) and placebo (9%; 20/225) groups experienced an adverse event during a follow-up of 3 to 72 months (RR 1.07, 95% CI 0.60 to 1.91; I² = 0%; low certainty evidence). Adverse event rates were similar in the 5-ASA and purine analogues groups. However, serious adverse events and withdrawals due to adverse events were more common in participants who received purine analogues than 5-ASA. At 52 weeks to 24 months, 52% (107/207) of 5-ASA participants had an adverse event compared to 47% (102/218) of purine analogue participants (RR 1.11, 95% CI 0.97 to 1.27, I² = 0%; low certainty evidence). Four per cent (6/152) of 5-ASA participants had a serious adverse event compared to 17% (27/159) of purine analogue participants (RR 0.30, 95% CI 0.11 to 0.80; very low certainty evidence). Eight per cent (17/207) of 5-ASA participants withdrew due to an adverse event compared to 19% (42/218) of purine analogue participants (RR 0.48, 95% CI 0.28 to 0.83; low certainty evidence). Adverse event rates were similar in high and low dose mesalamine participants. After 12 months, 2% (2/101) of 4 g/day mesalamine participants had an adverse event compared to 2% (2/105) of 2.4 g/day participants (RR 1.04, 95% CI 0.15 to 7.24; low certainty evidence). The proportion of participants who experienced adverse events over a 24 month follow-up in the mesalamine group was 78% (14/18) compared to 69% (11/16) of adalimumab participants (RR 1.13, 95% CI 0.75 to 1.71; very low certainty evidence). None (0/32) of th
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
(2008) · Cited by 3,790
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226
Predictability of the postoperative course of Crohn's disease
Rutgeerts, P., Geboes, K., Vantrappen, G., Beyls, J., Kerremans, R., & Hiele, M. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90613-6 · Cited by 1,820
National Cooperative Crohn's Disease Study: Results of drug treatment
Summers, R. W., Switz, D. M., Sessions, J. T., Becktel, J. M., Best, W. R., Kern, F., & Singleton, J. W. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90385-8 · Cited by 1,239
Rutgeerts, P., D'Haens, G., Targan, S., Vasiliauskas, E., Hanauer, S. B., Present, D. H., Mayer, L., Van Hogezand, R. A., Braakman, T., DeWoody, K. L., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70332-x · Cited by 1,080
European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment
Malchow, H., Ewe, K., Brandes, J. W., Goebell, H., Ehms, H., Sommer, H., & Jesdinsky, H. (1984) · Gastroenterology · doi:10.1016/0016-5085(84)90409-8 · Cited by 933
Van Assche, G., Dignass, A., Reinisch, W., van der Woude, C. J., Sturm, A., De Vos, M., Guslandi, M., Oldenburg, B., Dotan, I., Marteau, P., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.09.009 · Cited by 894
Chapter 12: Interpreting results and drawing conclusions
Schünemann, H. J., Oxman, A. D., Jonathan, J., & Glasziou, P. (2011) · Cited by 870
AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINE
Khan, A. K. A., Piris, J., & Truelove, S. C. (1977) · The Lancet · doi:10.1016/s0140-6736(77)90831-5 · Cited by 814
A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease
Feagan, B. G., Fedorak, R. N., Irvine, E. J., Wild, G., Sutherland, L., Steinhart, A. H., Greenberg, G. R., Koval, J., Wong, C. J., Hopkins, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006013422202 · Cited by 727
NUGENT, S. G., KUMAR, D., RAMPTON, D. S., & EVANS, D. F. (2001) · Gut · doi:10.1136/gut.48.4.571 · Cited by 700
Risk Factors for Surgery and Postoperative Recurrence in Crohn’s Disease
Bernell, O., Lapidus, A., & Hellers, G. (2000) · Annals of Surgery · doi:10.1097/00000658-200001000-00006 · Cited by 642
Rousseaux, C., Lefebvre, B., Dubuquoy, L., Lefebvre, P., Romano, O., Auwerx, J., Metzger, D., Wahli, W., Desvergne, B., Naccari, G. C., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041948 · Cited by 526
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
Wang, Y., Parker, C. E., Feagan, B. G., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000544.pub4 · Cited by 483
Self-citationHanauer, S. B., Korelitz, B. I., Rutgeerts, P., Peppercorn, M. A., Thisted, R. A., Cohen, R. D., & Present, D. H. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.06.002 · Cited by 460
Das, K. M., Eastwood, M. A., McManus, J. P. A., & Sircus, W. (1973) · New England Journal of Medicine · doi:10.1056/nejm197309062891001 · Cited by 445
Camma, C., Giunta, M., Rosselli, M., & Cottone, M. (1997) · Gastroenterology · doi:10.1053/gast.1997.v113.pm9352848 · Cited by 410
Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease
Chande, N., Patton, P. H., Tsoulis, D. J., Thomas, B. S., & MacDonald, J. K. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000067.pub3 · Cited by 402
Self-citationSVARTZ, N. (1942) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1942.tb06841.x · Cited by 364
Klotz, U., Maier, K., Fischer, C., & Heinkel, K. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012253032602 · Cited by 322
Numbers needed to treat derived from meta-analyses---sometimes informative, usually misleading
Smeeth, L., Haines, A., & Ebrahim, S. (1999) · BMJ · doi:10.1136/bmj.318.7197.1548 · Cited by 302
Lochs, H., Mayer, M., Fleig, W. E., Mortensen, P. B., Bauer, P., Genser, D., Petritsch, W., Raithel, M., Hoffmann, R., Gross, V., et al. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70208-3 · Cited by 298
Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn’s disease
Ardizzone, S., Maconi, G., Sampietro, G. M., Russo, A., Radice, E., Colombo, E., Imbesi, V., Molteni, M., Danelli, P. G., Taschieri, A. M., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.06.051 · Cited by 297
Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease
McLeod, R. S., Wolff, B. G., Hillary Steinhart, A., Carryer, P. W., O'Rourke, K., Andrews, D. F., Blair, J. E., Cangemi, J. R., Cohen, Z., Cullen, J. B., et al. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90327-5 · Cited by 265
Lichtenstein, G. R., Yan, S., Bala, M., & Hanauer, S. (2004) · American Journal of Gastroenterology · doi:10.1046/j.1572-0241.2003.04010.x · Cited by 265
Simpson's paradox and calculation of number needed to treat from meta-analysis
Cates, C. J. (2002) · BMC Medical Research Methodology · doi:10.1186/1471-2288-2-1 · Cited by 251
Probiotics for maintenance of remission in Crohn's disease
Rolfe, V. E., Fortun, P. J., Hawkey, C. J., & Bath-Hextall, F. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004826.pub2 · Cited by 251
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease
Behm, B. W., & Bickston, S. J. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006893 · Cited by 239
Corticosteroids for maintenance of remission in Crohn's disease
Steinhart, A. H., Ewe, K., Griffiths, A. M., Modigliani, R., & Thomsen, O. O. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000301 · Cited by 224
Ligumsky, M., Karmeli, F., Sharon, P., Zor, U., Cohen, F., & Rachmilewitz, D. (1981) · Gastroenterology · doi:10.1016/0016-5085(81)90594-1 · Cited by 217
CAPRILLI, R., ANDREOLI, A., CAPURSO, L., CORRAO, G., ALBASIO, G. D., GIOIENI, A., ASSUERO LANFRANCHI, G., PALADINI, I., PALLONE, F., PONTI, V., et al. (1994) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1994.tb00158.x · Cited by 213
Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease
Brignola, C., Cottone, M., Pera, A., Ardizzone, S., Scribano, M. L., de Franchis, R., D'Arienzo, A., D'Albasio, G., & Pennestri, D. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90059-4 · Cited by 206
Methotrexate for maintenance of remission in Crohn's disease
Patel, V., Wang, Y., MacDonald, J. K., McDonald, J. W., & Chande, N. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006884.pub3 · Cited by 180
Self-citationReinisch, W., Angelberger, S., Petritsch, W., Shonova, O., Lukas, M., Bar-Meir, S., Teml, A., Schaeffeler, E., Schwab, M., Dilger, K., et al. (2010) · Gut · doi:10.1136/gut.2009.194159 · Cited by 172
Recurrence of Crohn's disease after resection
Williams, J. G., Wong, W. D., Rothenberger, D. A., & Goldberg, S. M. (1991) · Journal of British Surgery · doi:10.1002/bjs.1800780106 · Cited by 165
Gendre, J., Mary, J., Florent, C., Modigliani, R., Colombel, J., Soulé, J., Galmiche, J., Lerebours, É., Descos, L., Viteau, J. M., et al. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90411-5 · Cited by 150
Modigliani, R., Colombel, J. F., Jl, D., Dapoigny, M. C., Costil, V., Veyrac, M., Duclos, B., Soulé, J. C., Jp, G., Jp, G., et al. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8608877 · Cited by 149
Prognostic factors for postoperative recurrence of Crohn's disease
Caprilli, R., Corrao, G., Taddei, G., et al. (1996) · Diseases of the Colon & Rectum · doi:10.1007/bf02049478 · Cited by 136
Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease
Prantera, C., Pallone, F., Brunetti, G., Cottone, M., & Miglioli, M. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90822-g · Cited by 132
SURGICAL THERAPY FOR ULCERATIVE COLITIS AND CROHN'S DISEASE
Becker, J. M. (1999) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(05)70061-3 · Cited by 132
Wenckert, A., Kristensen, M., Eklund, A., et al. (1978) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365527809181743 · Cited by 121
The Clinical Effect of Salazosulphapyridine (SalazopyrinR) in Crohn’s Disease
ANTHONISEN, P., Bárány, F., Folkenborg, O., Holtz, A., Jarnum, S., Kristensen, M., Riis, P., Walan, A., & WORNING, H. (1974) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.1974.12096873 · Cited by 106
Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects
Schröder, H., & Evans, D. A. P. (1972) · Gut · doi:10.1136/gut.13.4.278 · Cited by 105
Florent, C., Cortot, A., Quandale, P., et al. (1996) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-199603000-00008 · Cited by 105
Korelitz, B. I., Hanauer, S., Rutgeerts, P., et al. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)84115-2 · Cited by 103
Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis.
Steinhart, A. H., Hemphill, D. J., & Greenberg, G. R. (1994) · PubMed · Cited by 100
Risk and significance of endoscopic/radiological evidence of recurrent Crohn's disease
McLeod, R., Bg, W., Steinhart, A. H., et al. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70001-5 · Cited by 95
INTERNATIONAL MESALAZINE STUDY GROUP (1990) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1990.tb00449.x · Cited by 94
Caprilli, R., Cottone, M., Tonelli, F., Sturniolo, G. C., Castiglione, F., Annese, V., Papi, C., Viscido, A., Cammà, C., Corrao, G., et al. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01462.x · Cited by 91
ANTHONISEN, P., Bárány, F., Folkenborg, O., et al. (1974) · PubMed · Cited by 89
Maintenance therapy for inflammatory bowel disease
Feagan, B. G. (2003) · The American Journal of Gastroenterology · doi:10.1016/j.amjgastroenterol.2003.11.002 · Cited by 69
Assessment of long‐term quality of life after laparoscopic and open surgery for Crohn's disease
Thaler, K. J., Dinnewitzer, A., Oberwalder, M., Weiss, E. G., Nogueras, J. J., & Wexner, S. D. (2005) · Colorectal Disease · doi:10.1111/j.1463-1318.2005.00769.x · Cited by 67
Andersson, P., Olaison, G., Bendtsen, P., Myrelid, P., & Sjödahl, R. I. (2003) · Colorectal Disease · doi:10.1046/j.1463-1318.2003.00407.x · Cited by 65
Quality of Life Improves Within 30 Days of Surgery for Crohn’s Disease
Delaney, C. P., Kiran, R. P., Senagore, A. J., Ermlich, B., Church, J. M., Hull, T. L., Remzi, F. H., & Fazio, V. W. (2003) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(03)00131-5 · Cited by 57
Crohn's disease recurrence can be prevented after ileal resection
Rutgeerts, P. (2002) · Gut · doi:10.1136/gut.51.2.152 · Cited by 54
de Franchis, R., Omodei, P., Ranzi, T., Brignola, C., ROCCA, R., Prada, A., Pera, A., Vecchi, M. L., Piano, M. D., Ferrara, A. M., et al. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.00212.x · Cited by 51
Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease
Akobeng, A. K., & Stokkers, P. C. F. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007351.pub2 · Cited by 37
Self-citationMaintenance treatment of Crohn's disease
Biancone, L., Tosti, C., Fina, D., Fantini, M. C., Nigris, F. D., Geremia, A., & Pallone, F. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.17.s2.20.x · Cited by 34
Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease
Gordon, M. A., Naidoo, K., Thomas, A. G., & Akobeng, A. K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008414.pub2 · Cited by 33
Self-citationSchreiber, S., Howaldt, S. M., & Raedler, A. (1994) · Gut · doi:10.1136/gut.35.8.1081 · Cited by 31
Cézard, J., Munck, À., Mouterde, O., Morali, A., Lenaerts, C., Lachaux, A., Turck, D., Schmitz, J., Maurage, C., Girardet, J.-P., et al. (2009) · Gastroentérologie Clinique et Biologique · doi:10.1016/j.gcb.2008.07.007 · Cited by 29
Bresci, G., Parisi, G., & Banti, S. (1994) · PubMed · Cited by 25
Absorption, enterohepatic circulation, and excretion of 5-aminosalicylic acid in rats.
Shafii, A., Chowdhury, & Das, K. M. (1982) · PubMed · Cited by 23
Evidence-based treatment algorithm for mild to moderate Crohn's disease
Sandborn, W. J. (2003) · The American Journal of Gastroenterology · doi:10.1016/j.amjgastroenterol.2003.10.007 · Cited by 22
The case against routine post-operative therapy for prevention of recurrence in Crohn's disease.
Breslin, N., & Sutherland, L. (1998) · PubMed · Cited by 14
Papi, C., Aratari, A., Tornatore, V., Koch, M., Capurso, L., & Caprilli, R. (2009) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2008.12.001 · Cited by 10
Schwartz, D. (2005) · Evidence-Based Gastroenterology · doi:10.1097/01.ebg.0000154100.00152.9f · Cited by 4
Cited by
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Inflammatory bowel disease: clinical aspects and established and evolving therapies
Baumgart, D. C., & Sandborn, W. J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60751-x · Cited by 1,920
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
Guidelines for the management of inflammatory bowel disease in adults
Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., et al. (2011) · Gut · doi:10.1136/gut.2010.224154 · Cited by 1,419
ECCO guidelines on therapeutics in Crohn's disease: medical treatment
Torres, J., Bonovas, S., Doherty, G., Kucharzik, T., Gisbert, J. P., Raine, T., Adamina, M., Armuzzi, A., Bachmann, O., Bager, P., et al. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz180 · Cited by 1,374
Metadata
- Authors
- Akobeng, A. K., Zhang, D., Gordon, M., & MacDonald, J. K.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2016-09-28
- Volume
- 2016
- Issue
- 9
- Pages
- CD003715-CD003715
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1506954839
- Cited by
- 289
- References
- 72
- FWCI
- 11.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.